TY - JOUR
T1 - Multicenter clinical validation of a cartridge-based real-time pcr system for detection of coccidioides spp. In lower respiratory specimens
AU - Saubolle, Michael A.
AU - Wojack, Bette R.
AU - Wertheimer, Anne M.
AU - Fuayagem, Atehkeng Z.
AU - Young, Stephen
AU - Koeneman, Brian A.
N1 - Funding Information:
This study was funded by DxNA as part of the FDA submission for in vitro diagnostic device (IVD) clearance of the GeneSTAT system and GeneSTAT Coccidioides assay. Elizabeth Driebe and David Engelthaler of TGen are listed as inventors on the assay’s patent application. A portion of this work was supported by a fellowship for A.Z.F. from the Applied Biosciences Graduate Program (ABS-PSM GIDP). Stephen Young is on the Advisory Boards for Roche Molecular Systems, Inc., and Quidel, Inc.
Publisher Copyright:
© 2018 Saubolle et al.
PY - 2018/2
Y1 - 2018/2
N2 - Available methods for the diagnosis of coccidioidomycosis have significant shortcomings relative to accuracy and timeliness. We retrospectively and prospectively evaluated the diagnostic performance and reproducibility of a new cartridge-based real-time PCR assay for Coccidioides spp. directly in lower respiratory secretions and compared them to today's "gold standard,"fungal culture. The GeneSTAT Coccidioides assay uses a 106-bp target sequence repeated multiple times (∼60×) per genome, thus lowering the limit of detection (LOD) for extracted DNA to 10 genome equivalents/ml. A total of 332 prospective and retrospective individual patient specimens were tested. The retrospective samples consisted of 100 bronchoalveolar lavage or bronchial wash (BAL/BW) (51 positive and 49 negative by culture) specimens that had been collected previously and stored at -70°C. These samples were tested by the GeneSTAT Coccidioides assay across three clinical test sites. The sensitivity was 100%, and the specificity ranged between 93.8% and 100%. There was minimal variance in the percent agreement across the three sites, 95.6% to 100%. Additionally, a total of 232 fresh (prospective) deidentified BAL/BW specimens were tested across the three clinical sites, which included a number of specimens from Southern California to provide a diversity of isolates. Specimens were tested by fungal culture, with any isolates of Coccidioides, except for one, being confirmed by molecular means (AccuProbe). The sensitivity of the GeneSTAT Coccidioides assay across the three sites was 100% (4/4) for positive fresh specimens, and the overall specificity of the assay was 99.6% (227/228), ranging from 98.1% to 100%. In testing for cross-reactivity, the assay was 100% specific when screened against 47 different bacterial, viral, and fungal species.
AB - Available methods for the diagnosis of coccidioidomycosis have significant shortcomings relative to accuracy and timeliness. We retrospectively and prospectively evaluated the diagnostic performance and reproducibility of a new cartridge-based real-time PCR assay for Coccidioides spp. directly in lower respiratory secretions and compared them to today's "gold standard,"fungal culture. The GeneSTAT Coccidioides assay uses a 106-bp target sequence repeated multiple times (∼60×) per genome, thus lowering the limit of detection (LOD) for extracted DNA to 10 genome equivalents/ml. A total of 332 prospective and retrospective individual patient specimens were tested. The retrospective samples consisted of 100 bronchoalveolar lavage or bronchial wash (BAL/BW) (51 positive and 49 negative by culture) specimens that had been collected previously and stored at -70°C. These samples were tested by the GeneSTAT Coccidioides assay across three clinical test sites. The sensitivity was 100%, and the specificity ranged between 93.8% and 100%. There was minimal variance in the percent agreement across the three sites, 95.6% to 100%. Additionally, a total of 232 fresh (prospective) deidentified BAL/BW specimens were tested across the three clinical sites, which included a number of specimens from Southern California to provide a diversity of isolates. Specimens were tested by fungal culture, with any isolates of Coccidioides, except for one, being confirmed by molecular means (AccuProbe). The sensitivity of the GeneSTAT Coccidioides assay across the three sites was 100% (4/4) for positive fresh specimens, and the overall specificity of the assay was 99.6% (227/228), ranging from 98.1% to 100%. In testing for cross-reactivity, the assay was 100% specific when screened against 47 different bacterial, viral, and fungal species.
KW - Coccidioides spp.
KW - Coccidioidomycosis
KW - Fungal diagnosis
KW - PCR
KW - Valley fever
UR - http://www.scopus.com/inward/record.url?scp=85056568725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056568725&partnerID=8YFLogxK
U2 - 10.1128/JCM.01277-17
DO - 10.1128/JCM.01277-17
M3 - Article
C2 - 29212702
AN - SCOPUS:85056568725
SN - 0095-1137
VL - 56
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 2
M1 - e01277-17
ER -